TY - JOUR
T1 - Riociguat for the treatment of chronic thromboembolic pulmonary hypertension
AU - Ghofrani, Hossein Ardeschir
AU - D'Armini, Andrea M.
AU - Grimminger, Friedrich
AU - Hoeper, Marius M.
AU - Jansa, Pavel
AU - Kim, Nick H.
AU - Mayer, Eckhard
AU - Simonneau, Gerald
AU - Wilkins, Martin R.
AU - Fritsch, Arno
AU - Neuser, Dieter
AU - Weimann, Gerrit
AU - Wang, Chen
PY - 2013
Y1 - 2013
N2 - BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat. The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 minutes. Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clinical worsening, Borg dyspnea score, quality-of-life variables, and safety. RESULTS: By week 16, the 6-minute walk distance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m in the placebo group (least-squares mean difference, 46 m; 95% confidence interval [CI], 25 to 67; P-5in the riociguat group and increased by 23 dyn · sec · cm-5in the placebo group (least-squares mean difference, -246 dyn · sec · cm-5; 95% CI, -303 to -190; P
AB - BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat. The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 minutes. Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clinical worsening, Borg dyspnea score, quality-of-life variables, and safety. RESULTS: By week 16, the 6-minute walk distance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m in the placebo group (least-squares mean difference, 46 m; 95% confidence interval [CI], 25 to 67; P-5in the riociguat group and increased by 23 dyn · sec · cm-5in the placebo group (least-squares mean difference, -246 dyn · sec · cm-5; 95% CI, -303 to -190; P
UR - http://www.scopus.com/inward/record.url?scp=84880732460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880732460&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1209657
DO - 10.1056/NEJMoa1209657
M3 - Article
C2 - 23883377
AN - SCOPUS:84880732460
VL - 369
SP - 319
EP - 329
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 4
ER -